Brentuximab Vedotin
Brentuximab Vedotin is a targeted antibody-drug conjugate used to treat certain CD30-positive cancers, including classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It works by delivering chemotherapy directly to cancer cells while sparing most healthy tissue, making it a precise treatment option for these malignancies.
A targeted therapy for Hodgkin lymphoma and T-cell lymphomas that delivers chemotherapy directly to CD30-expressing cancer cells.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01FX05
- RxNorm
- 1147320
- Generic
- Brentuximab Vedotin
- Class
- atc-l01
- Brands
- Adcetris
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of classical Hodgkin lymphoma (cHL) in patients who have failed autologous stem cell transplant or who are not candidates for transplant, systemic anaplastic large cell lymphoma (sALCL), and other CD30-positive T-cell lymphomas.
An anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a potent chemotherapy agent. The antibody binds to CD30 on cancer cells, is internalized, and releases MMAE intracellularly, disrupting microtubules and causing cell death.
Administered as intravenous infusion, typically every 3 weeks. Common side effects include peripheral neuropathy, fatigue, nausea, and cytopenias. Requires regular blood monitoring. Should be administered under supervision of an oncologist. Risk of serious infusion reactions and potential fetal harm if used during pregnancy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy